Harrow Health Inc Stock Price, News & Analysis

Harrow (NASDAQ: HROW), a leading North American ophthalmic disease management solutions provider, has announced the pricing of $250.0 million senior unsecured notes due 2030. The notes will bear an interest rate of 8.625%, payable semi-annually starting March 15, 2026.

The proceeds will be used to repay multiple existing debts, including a $107.5 million Oaktree facility, $75.0 million of 8.625% Senior Notes (HROWL), and $40.25 million of 11.875% Senior Notes (HROWM). The offering, priced at 100% of principal amount, is expected to close on September 12, 2025, and is available only to qualified institutional buyers under Rule 144A.

Harrow (Nasdaq: HROW), a leading ophthalmic disease management solutions provider, has launched a private offering of $250.0 million senior unsecured notes due 2030. The company also secured a commitment for a new $40 million revolving credit facility with Fifth Third Bank.

The proceeds will be used to repay a $107.5 million Oaktree facility, redeem $75.0 million of 8.625% Senior Notes (HROWL) and $40.25 million of 11.875% Senior Notes (HROWM). Both HROWL and HROWM will be delisted from Nasdaq following redemption. The 2030 Notes will be guaranteed by Harrow's existing and future wholly-owned domestic restricted subsidiaries.

Harrow (NASDAQ: HROW), a leading ophthalmic solutions provider, reported strong Q2 2025 financial results with total revenues of $63.7 million, up 30% year-over-year. The company achieved GAAP net income of $5.0 million and Adjusted EBITDA of $17.0 million.

Key highlights include VEVYE®'s 66% sequential prescription growth with 50,000 new prescriptions and a 3% market share gain. The company secured exclusive U.S. rights to Samsung Bioepis' ophthalmology biosimilars (BYOOVIZ® and OPUVIZ™) and acquired BYQLOVI™ for post-operative inflammation treatment. Harrow maintains its forecast of over $280 million in revenue for 2025, with strong cash position of $53.0 million.

The company expanded its VEVYE® Access for All program through a strategic alliance with Apollo Care, adding 500+ pharmacies nationwide.

Harrow (NASDAQ: HROW), a leading North American eyecare pharmaceutical company, has announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Conference on August 13, 2025.

CEO Mark L. Baum and CFO Andrew Boll will participate in a fireside chat at 8:30 a.m. ET. Additionally, Baum will join a panel discussion on "Novel Treatments for Front-of-the-Eye Indications" at 1:00 p.m. ET. Both sessions will be available via webcast on the company's website, with replays accessible for 90 days after the event.

Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for August 11, 2025, after market close.

The company will release its quarterly Letter to Stockholders on its website and host a conference call with a live webcast on August 12, 2025, at 8:00 a.m. Eastern Time. Investors can access the webcast through Harrow's website, and telephone participants must register in advance to receive dial-in details.

Harrow (NASDAQ:HROW) has secured exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio through a definitive agreement. The portfolio includes BYOOVIZ® (ranibizumab-nuna), a LUCENTIS biosimilar, and OPUVIZ™ (aflibercept-yszy), an EYLEA biosimilar, for treating retinal diseases.

The transition from current commercialization partner Biogen is expected to complete by end of 2025. This strategic acquisition targets a $9 billion U.S. market opportunity in retinal disease treatment, with current anti-VEGF therapies accounting for over $4.2 billion in annual Medicare Part B spending. The deal positions Harrow as a leading full-spectrum ophthalmic pharmaceuticals provider, aiming to improve treatment accessibility and affordability.

Samsung Bioepis has partnered with Harrow (NASDAQ: HROW) for the commercialization of two ophthalmology biosimilars in the United States. The agreement covers BYOOVIZ® (ranibizumab-nuna), the first FDA-approved ophthalmology biosimilar, and OPUVIZ™ (aflibercept-yszy).

The commercial license will become effective after Biogen's rights transition back to Samsung Bioepis by the end of 2025. BYOOVIZ, approved in September 2021, has been available since June 2022, while OPUVIZ received FDA approval in May 2024. Both biosimilars target conditions including Wet Age-Related Macular Degeneration, Macular Edema, and other eye disorders.

Harrow (HROW), a leading North American eyecare pharmaceutical company, has appointed Mike Biega as Vice President of Investor Relations and Communications. Biega, who brings over a decade of biotech investor relations experience, succeeds Jamie Webb, who is retiring. Webb will remain until August to ensure a smooth transition. Biega previously served as Sr. Director of Investor Relations at Sensei Biotherapeutics and was a Managing Director at Solebury Trout. He began his career at Summer Street Research Partners in healthcare equity sales. CEO Mark L. Baum expressed enthusiasm about Biega's appointment, highlighting his experience in strengthening investor engagement and communications strategy.

Harrow (HROW) has acquired exclusive U.S. commercial rights to BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05% from Formosa Pharmaceuticals. BYQLOVI, recently FDA-approved for post-operative inflammation and pain following ocular surgery, is the first new ophthalmic steroid in its class in over 15 years. The drug utilizes Formosa's APNT nanoparticle technology and demonstrated superior clinical outcomes. Key highlights include 77-85% pain relief by Day 4, 82-87% by Day 8, and exceptional inflammation clearance with 30-33% of patients showing zero cell counts by Day 8. BYQLOVI features a low 1.4% rate of elevated intraocular pressure and simplified twice-daily dosing for 14 days. Launch is expected in Q4 2025, targeting a market of over 7 million annual ophthalmic surgeries.